Grade My Investments
HomeFree Stock Grades › ATRC

AtriCure, Inc. (ATRC) Stock Grade

ATRC · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.9B
P/E Ratio
Revenue Growth (YoY)
+14.9%
Net Margin
-2.1%
Return on Equity
Dividend Yield
None

About AtriCure, Inc.'s fundamentals

AtriCure is a $1.9 billion medical devices company experiencing solid revenue growth of 14.9% year-over-year, indicating expanding market demand for its products. However, the company currently operates at a net loss with a -2.1% net margin, meaning it spends more than it earns on an accounting basis. Despite this unprofitability, AtriCure generates positive free cash flow, suggesting its underlying operations produce cash even as accounting losses persist, which is not uncommon for growth-stage medical device companies investing heavily in expansion and development.

Track ATRC free — no credit card required. Live grade + monthly AI report →